Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study.

[1]  M. Mazidi,et al.  A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression , 2016, Journal of complementary & integrative medicine.

[2]  M. Marmot,et al.  The association of depressive symptoms with cardiovascular and all-cause mortality in Central and Eastern Europe: Prospective results of the HAPIEE study , 2016, European journal of preventive cardiology.

[3]  T. Laursen,et al.  Mortality and life expectancy in persons with severe unipolar depression. , 2016, Journal of affective disorders.

[4]  Dalia Al-Karawi,et al.  The Role of Curcumin Administration in Patients with Major Depressive Disorder: Mini Meta‐Analysis of Clinical Trials , 2016, Phytotherapy research : PTR.

[5]  M. Bauer,et al.  Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study , 2015, International Journal of Bipolar Disorders.

[6]  L. Pei,et al.  Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study , 2015, Journal of clinical psychopharmacology.

[7]  Hina Shakeel,et al.  Pretreatment with curcumin attenuates anxiety while strengthens memory performance after one short stress experience in male rats , 2015, Brain Research Bulletin.

[8]  G. Ferns,et al.  An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial , 2015, Chinese Journal of Integrative Medicine.

[9]  A. Talaei,et al.  Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. , 2015, Journal of affective disorders.

[10]  Y. Panahi,et al.  Investigation of the Efficacy of Adjunctive Therapy with Bioavailability‐Boosted Curcuminoids in Major Depressive Disorder , 2015, Phytotherapy research : PTR.

[11]  P. Drummond,et al.  Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action , 2014, Human psychopharmacology.

[12]  M. Maes,et al.  Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. , 2014, Journal of affective disorders.

[13]  Tasneem Khambaty,et al.  C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 , 2014, Journal of Behavioral Medicine.

[14]  A. Romane,et al.  A blunted anxiolytic like effect of curcumin against acute lead induced anxiety in rat: involvement of serotonin. , 2014, Acta histochemica.

[15]  A. Sahebkar.  Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis , 2014, Phytotherapy research : PTR.

[16]  A. Goel,et al.  Efficacy and Safety of Curcumin in Major Depressive Disorder: A Randomized Controlled Trial , 2014, Phytotherapy research : PTR.

[17]  S. Akhondzadeh,et al.  A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. , 2014, Journal of affective disorders.

[18]  S. Anton,et al.  Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. , 2013, Journal of integrative medicine.

[19]  B. Aggarwal,et al.  Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers , 2013, British journal of pharmacology.

[20]  A. Beekman,et al.  Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression , 2013, Molecular Psychiatry.

[21]  Y. Bersudsky,et al.  Curcumin as an Add-On to Antidepressive Treatment: A Randomized, Double-Blind, Placebo-Controlled, Pilot Clinical Study , 2013, Clinical neuropharmacology.

[22]  P. Drummond,et al.  Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects , 2012, Journal of psychopharmacology.

[23]  Derek Richards,et al.  Prevalence and clinical course of depression: a review. , 2011, Clinical psychology review.

[24]  Hongyu Zhou,et al.  The targets of curcumin. , 2011, Current drug targets.

[25]  G. Belcaro,et al.  Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. , 2010, Alternative medicine review : a journal of clinical therapeutic.

[26]  A. Gelenberg.  The prevalence and impact of depression. , 2010, The Journal of clinical psychiatry.

[27]  A. Levitt,et al.  The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review , 2010, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[28]  S. Joyal,et al.  A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95®CG (Biocurcumax™), A Novel Bioenhanced Preparation of Curcumin , 2008, Indian journal of pharmaceutical sciences.

[29]  Maurizio Fava,et al.  The STAR*D project results: A comprehensive review of findings , 2007, Current psychiatry reports.

[30]  J. Goethe,et al.  Selective Serotonin Reuptake Inhibitor Discontinuation: Side Effects and Other Factors That Influence Medication Adherence , 2007, Journal of clinical psychopharmacology.

[31]  S. Akhondzadeh,et al.  Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  C. Hoven,et al.  Use of complementary and alternative medicine among women with depression: results of a national survey. , 2007, Psychiatric services.

[33]  B. Tabachnick,et al.  Using Multivariate Statistics (5th Edition) , 2006 .

[34]  S. Akhondzadeh,et al.  Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. , 2005, Journal of ethnopharmacology.

[35]  S. Akhondzadeh,et al.  Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816] , 2004, BMC complementary and alternative medicine.

[36]  M. Parker,et al.  Ways of thinking about ethics , 2004 .

[37]  M H Trivedi,et al.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation , 2004, Psychological Medicine.

[38]  Thomas J. Carmody,et al.  The Inventory of Depressive Symptomatology (IDS): Clinician (IDS‐C) and Self‐Report (IDS‐SR) ratings of depressive symptoms , 2000 .

[39]  J. Guelfi,et al.  IDS-C and IDS-sr: psychometric properties in depressed in-patients. , 1999 .

[40]  L. Bauman,et al.  Content Validity of the Psychiatric Symptom Index, CES-Depression Scale, and State-Trait Anxiety Inventory from the Perspective of DSM-IV , 1996, Psychological reports.

[41]  A. Rush,et al.  The Inventory of Depressive Symptomatology (IDS): psychometric properties , 1996, Psychological Medicine.

[42]  A. Rush,et al.  The inventory for depressive symptomatology (IDS): Preliminary findings , 1986, Psychiatry Research.

[43]  Richard L. Metzger.  A reliability and validity study of the state-trait anxiety inventory , 1976 .

[44]  Kristi Williams,et al.  Atypical depression. , 2006, Psychiatry.

[45]  Richard L. Morris,et al.  Assessment of State and Trait Anxiety in Subjects with Anxiety and Depressive Disorders , 2004, Psychiatric Quarterly.

[46]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[47]  B. Tabachnick,et al.  Using Multivariate Statistics , 1983 .